Monday, 19 June 2017

Research Insights on Protein Phosphatase 2A (PP2A or EC - Pipeline Review, H1 2017

Protein Phosphatase 2A (PP2A or EC - Pipeline Review, H1 2017 is a new market research publication announced by Reportstack. This report Target constitutes close to 10 molecules. Out of which approximately 10 molecules are developed by Companies.
Protein Phosphatase 2A (PP2A or EC - Protein Phosphatase 2A (PP2A) is an enzyme encoded by the PPP2CA gene. PP2A plays important roles in regulation of cell cycle, signal transduction, cell differentiation, and transformation. Its activity is related to several diseases, including neurodegenerative diseases and cancer.
The report 'Protein Phosphatase 2A - Pipeline Review, H1 2017' outlays comprehensive information on the Protein Phosphatase 2A (PP2A or EC targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.
It also reviews key players involved in Protein Phosphatase 2A (PP2A or EC targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 5 and 3 respectively. Report covers products from therapy areas Oncology, Central Nervous System, Cardiovascular, Gastrointestinal, Ophthalmology and Respiratory which include indications Alzheimer's Disease, Glioblastoma Multiforme (GBM), Hepatocellular Carcinoma, Ovarian Cancer, Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), Allergic Conjunctivitis, Asthma, Brain Ischemia, Breast Cancer, Breast Tumor, Chronic Lymphocytic Leukemia (CLL), Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia), Chronic Obstructive Pulmonary Disease (COPD), Colon Cancer, Crohn's Disease (Regional Enteritis), Depression, Endometrial Cancer, Idiopathic Pulmonary Fibrosis, Lung Cancer, Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Myelodysplastic Syndrome, Myocardial Ischemia, Neuroblastoma, Neuroendocrine Tumors, Non-Small Cell Lung Cancer, Pancreatic Cancer, Parkinson's Disease, Prostate Cancer, Renal Cell Carcinoma, Septic Shock, Small-Cell Lung Cancer, Solid Tumor, T-Cell Leukemia, Ulcerative Colitis, Uveal Melanoma and Uveitis.
- The report provides a snapshot of the global therapeutic landscape for Protein Phosphatase 2A (PP2A or EC
- The report reviews Protein Phosphatase 2A (PP2A or EC targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in Protein Phosphatase 2A (PP2A or EC targeted therapeutics and enlists all their major and minor projects 
- The report assesses Protein Phosphatase 2A (PP2A or EC targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news and deals related to Protein Phosphatase 2A (PP2A or EC targeted therapeutics
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand the targeted therapy areas and indications for Protein Phosphatase 2A (PP2A or EC
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Protein Phosphatase 2A (PP2A or EC development landscape 
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Companies Mentioned
Ampio Pharmaceuticals Inc Bristol-Myers Squibb Company Cyano Biotech GmbH Lixte Biotechnology Holdings Inc PEP-Therapy SAS Re-Pharm Ltd Signum Biosciences Inc
Debora White
Manager - Marketing
Ph: +1-888-789-6604
ReportstackMarket Research


Post a Comment

Subscribe to Post Comments [Atom]

<< Home